SeaStar Medical (ICU) delivered the kind of headline revenue growth that usually draws attention, but the quarter's most important development came from its clinical timeline, not its sales line. The company reported a loss of $1.03 per share, missing the -$0.95 consensus by 8.4%. Revenue of $0.64 million beat the $0.5 million estimate by 27.0% and grew 247.0% year over year. Yet the NEUTRALIZE-AKI pivotal trial, the program that underpins most of the company's long-term value, slipped again, while cash fell to roughly $4.0 million. That is the central tension: a small commercial business that is beating expectations, attached to a larger development story that keeps getting pushed out.
The quality of both the beat and the earnings growth deserves scrutiny. The 20.8% year-over-year earnings improvement is a per-share effect. The net loss actually widened to $4.5 million from $3.5 million, and the per-share loss narrowed only because weighted-average shares rose to about 4.4 million from 2.7 million. The revenue acceleration is also partly a comparison effect. Year-over-year growth jumped from +69% in Q1 and +82% in Q2 to +247% in Q3, but that came against a soft $183 thousand prior-year quarter. Sequentially, QUELIMMUNE sales were essentially flat at about $635 thousand versus roughly $615 thousand in Q2, which an analyst questioned on the call. Gross margin stayed above 90%, which is impressive but immaterial against a cost base this size. Operating expenses rose to $5.2 million from $4.4 million in Q2. R&D nearly doubled year over year to $3.6 million on trial activity, and spending outpaced the roughly 5% quarterly R&D increase management had previously guided.
The call made the deceleration beneath the headline more explicit. The customer count held at 20, unchanged from Q2. That leaves the company well short of its 25-customer year-end goal, with only 10 new customers added in 2026 against a 15-customer target. Trial enrollment reached 251 of 339 patients, but only 28 were added in the quarter, barely ahead of Q2's pace and nowhere near the 15-20 per month management had aspired to. Enrollment completion now moves to mid-2027 from "year-end or Q1 2027." The final PMA module is expected about nine months after that, roughly Q1 2028, versus the end-2027 date management called "unchanged" just one quarter ago. The CEO said he was "clearly disappointed" and chose to be more conservative on timelines, a notable shift from the Q2 call's "never been higher" confidence.
The release still carried real positives. SAVE Registry data, presented as an ASN Kidney Week late-breaker, showed 65% versus 47% 90-day survival against a comparator cohort (p=0.043), with no device-related adverse events. FDA confirmed that the SAVE post-approval requirement has been fulfilled, removing the research-infrastructure burden that had limited hospital adoption. CMS ICD-10-PCS codes took effect October 1. The first modular PMA module has been submitted. A seventh Breakthrough Device Designation, this one for adult sepsis and hyperinflammation, aligns with a pre-specified sepsis subgroup that management estimates covers more than 70% of trial enrollees. Management now expects full-year QUELIMMUNE revenue to exceed $2 million, an upgrade from "advancing toward" that figure. However, reaching it implies Q4 sales of only about $255 thousand or more, a low bar. These developments could eventually reaccelerate pediatric adoption, but none of them has yet shown up in customer counts.
Financing is the most immediate risk. Cash has fallen from $12.0 million at year-end 2025 to $9.3 million, $7.0 million, and now about $4.0 million. Stockholders' equity has shrunk to $469 thousand. October warrant exercises added $3.3 million in gross proceeds, but with quarterly opex above $5 million and a trial that now runs longer, further dilution appears difficult to avoid before any adult approval.
The market had already priced in much of this skepticism. Shares were at $1.90 heading into the report, down 40.6% since the open following the August release. The stock was 42.5% below its 200-day moving average and had given back nearly all of an early-October spike to $4.80, ending just 3.3% above its inter-earnings low of $1.84. Investor sentiment remained positive but weakened meaningfully, slipping from 0.77 to 0.63. The trend readings are mixed: momentum is positive, while price and AVWAP trends remain negative.
The bottom line is that SeaStar's pediatric franchise is gaining regulatory and clinical credibility, but the quarter weakened the near-term investment setup. Revenue beat a modest bar on an easy comparison, while sequential sales, customer additions, the pivotal-trial timeline, and the cash balance all moved the wrong way. Until enrollment pace and customer growth visibly improve, investors are likely to weigh a longer, more expensive path to the adult AKI opportunity against a thin balance sheet.